[Form 4] DEXCOM INC Insider Trading Activity

Filing Impact

(Very High)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

DexCom Inc. executive Michael Jon Brown received a new equity award and had shares withheld for taxes. On March 8, 2026, he acquired 39,019 shares of Common Stock through a grant of restricted stock units (RSUs) that vest in three equal annual installments from the grant date.

On the same date, 23,325 shares of Common Stock were withheld by DexCom at $68.10 per share to cover tax withholding and remittance obligations in connection with RSU net settlement, which the disclosure notes does not represent a sale by Brown. After these transactions, he directly holds 114,604 shares of DexCom Common Stock, and this figure includes 77,603 unvested RSUs with various vesting schedules through March 8, 2029, as well as 255 shares acquired under the company’s Amended and Restated 2015 Employee Stock Purchase Plan.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Brown Michael Jon

Role EVP, Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	39,019	$0.00	--
Tax Withholding	Common Stock	23,325	$68.10	$1.59M

Holdings After Transaction: Common Stock — 137,929 shares (Direct)

Footnotes (1)

Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person. Included in this number are 77,603 unvested RSUs, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 255 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan.

Form 4 Insider Transactions: What Each Field Means →

03/10/2026 - 04:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brown Michael Jon

(Last)

(First)

(Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/08/2026		A		39,019⁽¹⁾	A	$0	137,929	D
Common Stock	03/08/2026		F		23,325⁽²⁾	D	$68.1	114,604⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock.

2. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person.

3. Included in this number are 77,603 unvested RSUs, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 255 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Michael Jon Brown	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did DexCom (DXCM) executive Michael Jon Brown report on this Form 4?

Michael Jon Brown reported a grant of restricted stock units and related tax withholding. He received 39,019 RSU-based Common Stock shares and had 23,325 shares withheld by DexCom to satisfy tax obligations tied to RSU settlement.

How many DexCom (DXCM) shares did Michael Jon Brown acquire in this transaction?

He acquired 39,019 shares of DexCom Common Stock through a restricted stock unit grant. These RSUs vest in three equal annual installments from the March 8, 2026 grant date, representing equity-based compensation rather than an open-market purchase.

Why were 23,325 DexCom (DXCM) shares disposed of in Brown’s Form 4 filing?

The 23,325 shares were withheld by DexCom to cover tax withholding and remittance obligations for net settlement of RSUs. The filing specifies this withholding does not represent a sale by Michael Jon Brown in the open market.

What is Michael Jon Brown’s DexCom (DXCM) shareholding after these transactions?

Following the reported transactions, Michael Jon Brown directly holds 114,604 shares of DexCom Common Stock. This total includes 77,603 unvested RSUs and 255 shares acquired under DexCom’s Amended and Restated 2015 Employee Stock Purchase Plan.

How are Michael Jon Brown’s new DexCom (DXCM) RSUs structured for vesting?

The 39,019 RSUs granted on March 8, 2026 vest in three equal annual installments through March 8, 2029. Additional unvested RSUs from prior grants continue vesting through dates in 2027 and 2028, according to the disclosure footnotes.

Is the Form 4 for DexCom (DXCM) an open-market buy or sell by Michael Jon Brown?

The Form 4 reflects a compensation-related RSU grant and tax withholding, not open-market trading. Shares were acquired via RSU award, and shares marked as disposed were withheld by DexCom to satisfy tax obligations, not sold by Brown.